Vienna Study: Peptide from Cone Snail Venom Inhibits Pain Without Opioids

Mechanism of Action Without Opioid Receptors

The special feature of the active substance lies in its mechanism: that "AoIA" does not act on opioid receptors and other known target structures of pain processing. Instead, "AoIA" selectively influences only the noradrenaline transporter, but not the closely related transport proteins for serotonin or dopamine. The compound specifically inhibits the noradrenaline transporter and can thereby support the body's own pain-inhibiting mechanisms.

In animal models, "AoIA" exerts its effect in an inflammation-related pain phase after just a single subcutaneous injection. There were no signs of sedation or impaired movement coordination. This observation is considered an indication that the active substance may avoid certain side effects of classical painkillers.

Advantages Over Older Conotoxin Compounds

Compared with the peptide "MrIA" discovered 25 years ago from the same family of Chi-conotoxins, which must be administered directly into the cerebrospinal fluid, AoIA would be significantly easier to use. Compared with the peptide "MrIA" discovered 25 years ago from the same family of Chi-conotoxins, the researchers therefore see a clinical advantage, as Sitte explained in a press release.

According to Sitte, the results "lay an important foundation for the development of new non-opioid pain medications with significantly simpler application". However, further preclinical and clinical studies are required before potential use in humans. The team did not name concrete timelines for clinical trials.

Cone Snails as the Pharmacy of the Seas

Cone snails use venom to capture prey and defend against enemies, which is injected into the prey via a type of harpoon. A typical venom of these animals contains hundreds to thousands of bioactive substances. Thousands of so-called conotoxin sequences are already known, the venom cocktails of the roughly 750 species comprising the genus Conus.

These compounds can also act on the human nervous system, docking onto receptors that are important for pain signal transmission. Conotoxins have therefore been considered for years one of the most productive sources of novel pharmacological lead structures. The research group in Vienna places its results within this larger line of research.

Outlook on Further Fields of Application

The study provides a mechanistic blueprint for how a single peptide from a species-rich venom cocktail specifically intervenes in the pain circuit. Because AoIA docks only at a narrowly defined molecular site, the authors also see this as an approach to reducing unwanted effects on other neurotransmitter systems. This is an advantage over less selective substances.

In addition to pain research, the noradrenaline transporter is also considered a target structure for antidepressants. The fact that AoIA selectively binds to this transporter could therefore be relevant beyond pain treatment for further neurological and psychiatric questions, the team writes. Further preclinical data are expected to show which of these possibilities will actually be pursued clinically.

The Vienna findings appear at a time when the search for alternatives to opioid-containing painkillers is being intensified internationally. Chronic pain is one of the most common causes of reduced quality of life; new treatment options are therefore also in demand from a health policy perspective. According to the research group's assessment, AoIA could add another building block, provided that upcoming studies confirm the previous findings.